U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Brolucizumab

Last Revision: May 15, 2022.

Estimated reading time: 1 minute

CASRN: 1531589-13-5

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of brolucizumab during breastfeeding. Brolucizumab inhibits vascular endothelial growth factor (VEGF). Because it is a large protein molecule with a molecular weight of 26,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. The manufacturer states that breastfeeding is not recommended during treatment and for at least one month after the last dose. Since VEGF is present in human milk and is thought to help in maturation of the infant’s gastrointestinal tract, concern has been raised about the maternal use of VEGF inhibitors during breastfeeding. Note that the typical alternative to breastmilk is infant formula, which contains no VEGF.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Intravitreal) Bevacizumab, Ranibizumab

Substance Identification

Substance Name

Brolucizumab

CAS Registry Number

1531589-13-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Angiogenesis Inhibitors

Antibodies, Monoclonal

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

  • Review Faricimab[Drugs and Lactation Database (...]
    Review Faricimab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Bevacizumab[Drugs and Lactation Database (...]
    Review Bevacizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ziv-Aflibercept[Drugs and Lactation Database (...]
    Review Ziv-Aflibercept
    . Drugs and Lactation Database (LactMed). 2006
  • Review Conbercept[Drugs and Lactation Database (...]
    Review Conbercept
    . Drugs and Lactation Database (LactMed). 2006
  • Review Aflibercept[Drugs and Lactation Database (...]
    Review Aflibercept
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...